Overview

Actuate 1901: 9-ING-41 in Myelofibrosis

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.

Phase:

Phase 2

Details

Lead Sponsor:

Actuate Therapeutics Inc.

Collaborator:

Developmental Therapeutics Consortium